China's National Medical Products Administration (NMPA) appr
文 / 小金
2026-09-10 12:02:02
来源:亚金网
China's National Medical Products Administration (NMPA) approved semaglutide injection (brand: Nuoheying®) for metabolic dysfunction‑associated steatohepatitis (MASH) with moderate-to-severe liver fibrosis (F2–F3) in non-cirrhotic adults, making it the first and only GLP-1RA approved for MASH.
